Method for predicting the sensitivity of a patient suffering of renal cell carcinoma to Sunitinib treatment.

OFFER from France, reference: TOFR20171115007, valid from 05-12-2017 untill 06-12-2018

Technology
  • Title:
    Method for predicting the sensitivity of a patient suffering of renal cell carcinoma to Sunitinib treatment.
  • Start date:
    5 december 2017 (2 weken geleden)
  • End date:
    6 december 2018
  • Summary:
    A French laboratory has identified a biomarker and developed a diagnostic test for predicting or evaluating the response of patients with renal cell carcinoma to the reference first-line treatment (i.e. Sunitinib). They are currently looking for industrial partners interested in technology licensing-in and R&D collaboration (possible co-funding for maturation phase).
  • Description:
    A French laboratory, which has developed a method for predicting the sensitivity of a patient suffering of renal cell carcinoma to Sunitinib treatment is looking for industrial partners.

    Renal cell carcinoma (RCC) is the most common type of kidney cancer in adult, being responsible for approximately 90% of all cases in adults. Clear cell renal cell carcinoma (ccRCC) is the most common form of RCC (75-80%). Metastatic ccRCC is the most lethal of all the genitourinary tumors.

    Sunitinib is a tyrosine kinase inhibitor established as first-line therapy since 2013 and still the leading therapy for RCC, in particular for advanced and metastatic RCC (NCCN - National Comprehensive Cancer Network, ESMO - European Society for Medical Oncology- and EAU - European Association of Urology- guidelines). However, a majority of patients treated with Sunitinib become ineluctably non-respondent in 6-15 months. Moreover, in the majority of patients, there is no visible clinical improvement by imaging after only one or two cycles of treatment with Sunitinib (1 cycle = 4 weeks). Until now, no reliable tests have been able to predict resistance to Sunitinib treatment.

    The technology is based on the discovery by inventors of an early predicting serological biomarker of response to Sunitinib of clear cell renal cell carcinoma (ccRCC) or metastatic ccRCC.

    A decrease or absence of variation in serum concentration of the biomarker between inclusion and treatment is predicting a good response to Sunitinib. In contrast, an increase of the biomarker in serum concentration is predicting an absence of response to Sunitinib.

    This test allows the prediction of response to Sunitinib treatment for patients suffering from ccRCC or metastatic ccRCC in order to anticipate the patients’ resistance to Sunitinib and propose alternative treatments to non-responsive ones (i.e. chemotherapeutic treatments such as Axitinib, Pazopanib, Pazopanib, Cabozantinib, Everolimus or immunotherapies with the Nivolumab).
    The French laboratory looks for industrial partners such as:
    - a diagnostic company with an expertise in diagnostic kit development, specifically in cancer
    - a pharmaceutical/biotech company on the market of renal cancer

    The laboratory offers technology licensing-in. This way, the partner will further develop and then exploit directly the technology according to the license agreement.

    The laboratory is also open to research cooperation agreement to work on the maturation phase of the technology in partnership with the industrial partner.

Partner Sought
  • Type of Partnership Considered:
    License agreement, Research cooperation agreement
  • Technical Specification or Expertise Sought:

    The laboratory is currently looking for industrial partners interested in technology licensing-in and R&D collaboration (possible co-funding for technology maturation):

    • a diagnostic company with an expertise in diagnostic kit development, specifically in cancer

    • a pharmaceutical/biotech company on the market of renal cancer

    SME 11-50,SME <10,>500 MNE,251-500,SME 51-250,>500

Organisation
  • Development stage:
    Under development/lab tested
  • IPR Status:
    Patent(s) applied for but not yet granted
  • Market keywords:
    Diagnostic test products and equipment
    In-vitro diagnostics
    Molecular diagnosis
    Oncology
  • Technology keywords:
    Diagnostics, Diagnosis
    In vitro Testing, Trials
  • NACE keywords:
  • Advantages and Innovations:
    Clinicians select first-line treatments for RCC by only assessing the toxicity, comorbidities, risk profiles and cost of the therapeutic options. Given the volume of approved drugs for RCC, there is still a clinical unmet need for biomarkers to help optimize therapy choice.

    Indeed, while various biomarkers have been identified in RCC, the disease’s heterogeneity has hindered efforts to identify clinically viable biomarkers. In the absence of predictive biomarkers, targeted therapies continue to be used in a non-targeted manner.

    A predictive marker of response to Sunitinib allowing an accurate selection of patients capable of responding to Sunitinib, the first-line standard, is a solution for patients to receive the most appropriate therapy as soon as possible and avoid a possibly toxic one:

    • Non-invasive biomarker, present in the human serum
    • Early biomarker: supports clinical decision after the first cycle of Sunitinib treatment (4 weeks), without waiting for patients to become refractory
    • Sensitivity: identification of patients that are sensitive to Sunitinib for a long period of treatment
    • Specificity: a predictive biomarker of response to Sunitinib and not correlated to other chemotherapies, bevacizumab or interferon

    The test could be useful after 2 cycles of treatment of ccRCC and metastasic ccRCC.
Client
  • Type and Size of Organisation:
    Other
  • Already Engaged in Trans-National Cooperation
    Nee
  • Year Established:
    2012
  • Turnover:
  • Country of origin:
    France
  • Languages spoken
    • English
    • French